Fulcrum Therapeutics (FULC) risk factors, FY2025 10-K

Risks Related to our Financial Position and Need for Additional Capital

1. 01We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability23% rewritten
2. 02add operational, financial and management information systems and personnel, including personnel to support our product development and any future commercialization efforts, as needed, and our operations as a public company
3. 03there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim
4. 04We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts
5. 05the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights
6. 06Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
7. 07Our operations have been focused on research and development and conducting clinical trials, which may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability
8. 08Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition44% rewritten
9. 09Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations54% rewritten
10. 10We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses or research and development tax credit carryforwards23% rewritten

Risks Related to the Discovery and Development of our Product Candidates

1. 11We are early in our development efforts and we currently have one product candidate in active clinical development. If we are unable to commercialize directly or out-license to a third party any of our product candidates or experience significant delays in doing so, our business will be materially harmed23% rewritten
2. 12maintaining a continued acceptable safety profile following receipt of any regulatory approvals
3. 13We may not be successful in our efforts to build a pipeline of product candidates
4. 14Further, in February 2023, the FDA imposed a clinical hold on our IND for pociredir in SCD, which halted our clinical trial until the FDA lifted the clinical hold in August 2023
5. 15have the product removed from the market after obtaining marketing approval
6. 16If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented22% rewritten
7. 17Our inability to locate and enroll a sufficient number of eligible patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals
8. 18If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of our product candidate
9. 19In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound
10. 20If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised
11. 21We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
12. 22We are conducting a clinical trial of pociredir in patients with SCD that includes clinical trial sites in Africa, and the FDA may not accept data from these trial sites or others located outside the United States23% rewritten

Risks Related to the Commercialization of our Product Candidates

1. 23any restrictions on the use of our products, if approved, together with other medications
2. 24If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved
3. 25unforeseen costs and expenses associated with creating an independent sales and marketing organization
4. 26We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
5. 27For example, we are aware of several product candidates in clinical development that could be competitive with product candidates that we may successfully develop and commercialize. See Item 1 “Business – Competition” for additional information
6. 28We rely, and expect to continue to rely, on CMOs to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed
7. 29Our reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or if approved, products at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts26% rewritten
8. 30Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business
9. 31neither experimental nor investigational
10. 32Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business
11. 33Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
12. 34the inability to commercialize any products that we may develop

Risks Related to our Dependence on Third Parties

1. 35We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may harm our business27% rewritten
2. 36Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities28% rewritten
3. 37If we are not able to establish collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected45% rewritten
4. 38Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced number of potential future collaborators

Risks Related to our Intellectual Property

1. 39Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
2. 40If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed
3. 41If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, our business may be materially harmed
4. 42Our issued European patents could be subject to the jurisdiction of the UPC
5. 43Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 44Although we or our licensors are not currently involved in any litigation to protect or enforce our patent or other intellectual property rights, we may become involved in such lawsuits, which could be expensive, time-consuming and unsuccessful
7. 45Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
8. 46Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities
9. 47Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 48If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
11. 49the priority of invention of patented technology
12. 50We may not be able to protect our intellectual property and proprietary rights throughout the world
13. 51We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
14. 52If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
15. 53Intellectual property rights do not necessarily address all potential threats

Risks Related to Regulatory Approval of our Product Candidates and Other Legal Compliance Matters

1. 54preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viableNew
2. 55If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired61% rewritten
3. 56We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing productsNew
4. 57Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition
5. 58Designations by the FDA, such as fast track designation or breakthrough therapy designation, may not lead to a faster development or regulatory review or approval process, and do not increase the likelihood that our product candidates will receive marketing approval
6. 59Even if the FDA agrees that we may pursue an accelerated approval NDA submission, approval of the NDA is not assured, nor does submission of an accelerated approval NDA ensure that the product candidate will have a faster development or regulatory review process
7. 60Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval
8. 61Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates from being marketed abroad
9. 62litigation involving patients using our products
10. 63The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products50% rewritten
11. 64Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidate and affect the prices we may obtain for any products that are approved in the United States or foreign jurisdictions34% rewritten
12. 65the availability of capital
13. 66Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any
14. 67If we or any third-party manufacturers we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could harm our business
15. 68Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation
16. 69Our internal computer and information technology systems and infrastructure, or those of our collaborators or other contractors or consultants, may fail or suffer security compromises or breaches, which could result in a disruption of our product development programs

Risks Related to Employee Matters and Managing Growth

1. 70Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel
2. 71We expect to expand our development and regulatory capabilities and, if appropriate, potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations

Risks Related to our Common Stock

1. 72Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval
2. 73Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management
3. 74require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws
4. 75If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline
5. 76The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders
6. 77the other factors described in this “Risk Factors” section
7. 78A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well
8. 79We are a “smaller reporting company,” and the scaled disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
9. 80reduced disclosure obligations regarding executive compensation
10. 81We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
11. 82Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gain
12. 83Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees